Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Onto Innovation Inc ONTO

Onto Innovation Inc. is engaged in the design, development, manufacture and support of metrology and inspection tools for the semiconductor industry. The Company’s products include Automated Metrology Systems; Integrated Metrology Systems; Silicon Wafer All-surface Inspection/Characterization; Macro Defect Inspection; Automated Defect Classification and Pattern Analysis; Yield Analysis; Opaque... see more

Recent & Breaking News (NYSE:ONTO)

Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer

Business Wire November 15, 2016

NANOBIOTIX Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as in Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting

Business Wire November 14, 2016

Nanobiotix présente des résultats précliniques sur une nouvelle utilisation de NBTXR3 comme potentiel vaccin in situ contre le cancer, lors du congrès annuel de la Society for Immunotherapy of Cancer

Business Wire November 14, 2016

Nordic Nanovector to Present at Jefferies 2016 London Healthcare Conference

Business Wire November 14, 2016

Nanobiotix : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Business Wire November 7, 2016

Nordic Nanovector: Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®

Business Wire November 4, 2016

Nordic Nanovector: Results From Preclinical Studies of Betalutin® in Combination with Rituximab in non-Hodgkin Lymphoma Model to Be Presented at ASH

Business Wire November 3, 2016

Nordic Nanovector: Updated Results from Phase 1/2 Trial of Betalutin® in Non-Hodgkin Lymphoma to be Presented at ASH Annual Meeting in December

Business Wire November 3, 2016

Mid-Morning Market Update: Markets Mostly Higher; Mastercard Beats Q3 Views

Benzinga.com  October 28, 2016

Nanometrics Reports Third Quarter 2016 Financial Results

GlobeNewswire October 27, 2016

Nordic Nanovector and Heidelberg Pharma enter collaboration to develop novel antibody-drug conjugates (ADCs) targeting leukaemias

Business Wire October 26, 2016

Nanobiotix’s Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia

Business Wire October 21, 2016

PharmaEngine, partenaire de Nanobiotix, a lancé en Asie un nouvel essai clinique avec le NBTXR3, chez les patients atteints de cancers de la tête et du cou

Business Wire October 21, 2016

Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia

GlobeNewswire October 20, 2016

Nordic Nanovector ASA: Issuance of Restricted Stock Units (RSUs) to the New Board Member Joanna Horobin

Business Wire October 20, 2016

Nordic Nanovector Announces the Appointment of Joanna Horobin, MD, as Non-Executive Board Director

Business Wire October 12, 2016

Nordic Nanovector ASA: Extraordinary General Meeting Held

Business Wire October 12, 2016

Nanobiotix : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Business Wire October 11, 2016

Nanometrics to Announce Third Quarter Financial Results on October 27, 2016

GlobeNewswire October 10, 2016

Nordic Nanovector and LegoChem Biosciences Enter Collaboration to Develop Novel Antibody-Drug Conjugates (ADCs) Targeting Leukaemias

Business Wire October 10, 2016